Antimicrobial peptides: potential use in skin infections
Antimicrobial peptides are part of the natural defense against infections in all phyla, including humans. Antimicrobial peptides are considered to be promising alternatives to conventional antimicrobials. Antimicrobial peptides are active against a wide spectrum of pathogens, including multidrug-res...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical dermatology 2003, Vol.4 (9), p.591-595 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 595 |
|---|---|
| container_issue | 9 |
| container_start_page | 591 |
| container_title | American journal of clinical dermatology |
| container_volume | 4 |
| creator | Ulvatne, Hilde |
| description | Antimicrobial peptides are part of the natural defense against infections in all phyla, including humans. Antimicrobial peptides are considered to be promising alternatives to conventional antimicrobials. Antimicrobial peptides are active against a wide spectrum of pathogens, including multidrug-resistant bacteria, fungi, viruses and parasites. Thus, they are promising candidates for treatment of various skin infections, also infections caused by bacteria such as methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci. However, there are some obstacles, e.g. low tissue penetrability, high production costs, and unknown cytotoxicity, to overcome before antimicrobial peptides will be readily available for the treatment of infectious diseases. Topical administration may solve some of these problems. Some antimicrobial peptides are currently in clinical trials, including peptides developed for treatment of skin infections. |
| doi_str_mv | 10.2165/00128071-200304090-00001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73565712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73565712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-32c34a8e64171aebb2d9b16119638171553c97bcb16474c04d7179749041dba3</originalsourceid><addsrcrecordid>eNpFkEtPwzAMx3MAsTH4CqgnbgU7z4bbNMFAmsRl9yhJMynQF0174NsT2ABbsqW_X_KPkALhjqIU9wBIK1BYUgAGHDSUkA3PyBJRiRKExAW5TOkNgGaXF2SBVFOplVqSat1NsY1-7F20TTGEYYp1SA_F0E8hl7I2p1DErkjvOcTuEPwU-y5dkfODbVK4PuUV2T897jfP5e51-7JZ70pPKzGVjHrGbRUkR4U2OEdr7VAiasmqLAnBvFbOZ40r7oHXCpVWXAPH2lm2IrfHtcPYf8whTaaNyYemsV3o52QUE1IopLmxOjbmV1Iaw8EMY2zt-GkQzDco8wvK_IEyP6Dy6M3pxuzaUP8PniixL17kY_U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73565712</pqid></control><display><type>article</type><title>Antimicrobial peptides: potential use in skin infections</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ulvatne, Hilde</creator><creatorcontrib>Ulvatne, Hilde</creatorcontrib><description>Antimicrobial peptides are part of the natural defense against infections in all phyla, including humans. Antimicrobial peptides are considered to be promising alternatives to conventional antimicrobials. Antimicrobial peptides are active against a wide spectrum of pathogens, including multidrug-resistant bacteria, fungi, viruses and parasites. Thus, they are promising candidates for treatment of various skin infections, also infections caused by bacteria such as methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci. However, there are some obstacles, e.g. low tissue penetrability, high production costs, and unknown cytotoxicity, to overcome before antimicrobial peptides will be readily available for the treatment of infectious diseases. Topical administration may solve some of these problems. Some antimicrobial peptides are currently in clinical trials, including peptides developed for treatment of skin infections.</description><identifier>ISSN: 1175-0561</identifier><identifier>DOI: 10.2165/00128071-200304090-00001</identifier><identifier>PMID: 12926977</identifier><language>eng</language><publisher>New Zealand</publisher><subject>Anti-Infective Agents - pharmacology ; Anti-Infective Agents - therapeutic use ; Antimicrobial Cationic Peptides - pharmacology ; Antimicrobial Cationic Peptides - therapeutic use ; Enterococcus - drug effects ; Humans ; Methicillin Resistance ; Microbial Sensitivity Tests ; Skin Diseases, Infectious - drug therapy ; Staphylococcal Infections - drug therapy ; Staphylococcus aureus - drug effects ; Vancomycin Resistance</subject><ispartof>American journal of clinical dermatology, 2003, Vol.4 (9), p.591-595</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c285t-32c34a8e64171aebb2d9b16119638171553c97bcb16474c04d7179749041dba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27902,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12926977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ulvatne, Hilde</creatorcontrib><title>Antimicrobial peptides: potential use in skin infections</title><title>American journal of clinical dermatology</title><addtitle>Am J Clin Dermatol</addtitle><description>Antimicrobial peptides are part of the natural defense against infections in all phyla, including humans. Antimicrobial peptides are considered to be promising alternatives to conventional antimicrobials. Antimicrobial peptides are active against a wide spectrum of pathogens, including multidrug-resistant bacteria, fungi, viruses and parasites. Thus, they are promising candidates for treatment of various skin infections, also infections caused by bacteria such as methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci. However, there are some obstacles, e.g. low tissue penetrability, high production costs, and unknown cytotoxicity, to overcome before antimicrobial peptides will be readily available for the treatment of infectious diseases. Topical administration may solve some of these problems. Some antimicrobial peptides are currently in clinical trials, including peptides developed for treatment of skin infections.</description><subject>Anti-Infective Agents - pharmacology</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antimicrobial Cationic Peptides - pharmacology</subject><subject>Antimicrobial Cationic Peptides - therapeutic use</subject><subject>Enterococcus - drug effects</subject><subject>Humans</subject><subject>Methicillin Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Skin Diseases, Infectious - drug therapy</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Vancomycin Resistance</subject><issn>1175-0561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtPwzAMx3MAsTH4CqgnbgU7z4bbNMFAmsRl9yhJMynQF0174NsT2ABbsqW_X_KPkALhjqIU9wBIK1BYUgAGHDSUkA3PyBJRiRKExAW5TOkNgGaXF2SBVFOplVqSat1NsY1-7F20TTGEYYp1SA_F0E8hl7I2p1DErkjvOcTuEPwU-y5dkfODbVK4PuUV2T897jfP5e51-7JZ70pPKzGVjHrGbRUkR4U2OEdr7VAiasmqLAnBvFbOZ40r7oHXCpVWXAPH2lm2IrfHtcPYf8whTaaNyYemsV3o52QUE1IopLmxOjbmV1Iaw8EMY2zt-GkQzDco8wvK_IEyP6Dy6M3pxuzaUP8PniixL17kY_U</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Ulvatne, Hilde</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2003</creationdate><title>Antimicrobial peptides: potential use in skin infections</title><author>Ulvatne, Hilde</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-32c34a8e64171aebb2d9b16119638171553c97bcb16474c04d7179749041dba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Anti-Infective Agents - pharmacology</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antimicrobial Cationic Peptides - pharmacology</topic><topic>Antimicrobial Cationic Peptides - therapeutic use</topic><topic>Enterococcus - drug effects</topic><topic>Humans</topic><topic>Methicillin Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Skin Diseases, Infectious - drug therapy</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Vancomycin Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ulvatne, Hilde</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ulvatne, Hilde</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial peptides: potential use in skin infections</atitle><jtitle>American journal of clinical dermatology</jtitle><addtitle>Am J Clin Dermatol</addtitle><date>2003</date><risdate>2003</risdate><volume>4</volume><issue>9</issue><spage>591</spage><epage>595</epage><pages>591-595</pages><issn>1175-0561</issn><abstract>Antimicrobial peptides are part of the natural defense against infections in all phyla, including humans. Antimicrobial peptides are considered to be promising alternatives to conventional antimicrobials. Antimicrobial peptides are active against a wide spectrum of pathogens, including multidrug-resistant bacteria, fungi, viruses and parasites. Thus, they are promising candidates for treatment of various skin infections, also infections caused by bacteria such as methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci. However, there are some obstacles, e.g. low tissue penetrability, high production costs, and unknown cytotoxicity, to overcome before antimicrobial peptides will be readily available for the treatment of infectious diseases. Topical administration may solve some of these problems. Some antimicrobial peptides are currently in clinical trials, including peptides developed for treatment of skin infections.</abstract><cop>New Zealand</cop><pmid>12926977</pmid><doi>10.2165/00128071-200304090-00001</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1175-0561 |
| ispartof | American journal of clinical dermatology, 2003, Vol.4 (9), p.591-595 |
| issn | 1175-0561 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73565712 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Anti-Infective Agents - pharmacology Anti-Infective Agents - therapeutic use Antimicrobial Cationic Peptides - pharmacology Antimicrobial Cationic Peptides - therapeutic use Enterococcus - drug effects Humans Methicillin Resistance Microbial Sensitivity Tests Skin Diseases, Infectious - drug therapy Staphylococcal Infections - drug therapy Staphylococcus aureus - drug effects Vancomycin Resistance |
| title | Antimicrobial peptides: potential use in skin infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T09%3A24%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20peptides:%20potential%20use%20in%20skin%20infections&rft.jtitle=American%20journal%20of%20clinical%20dermatology&rft.au=Ulvatne,%20Hilde&rft.date=2003&rft.volume=4&rft.issue=9&rft.spage=591&rft.epage=595&rft.pages=591-595&rft.issn=1175-0561&rft_id=info:doi/10.2165/00128071-200304090-00001&rft_dat=%3Cproquest_cross%3E73565712%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73565712&rft_id=info:pmid/12926977&rfr_iscdi=true |